ZA945939B - Insulin formulation - Google Patents
Insulin formulationInfo
- Publication number
- ZA945939B ZA945939B ZA945939A ZA945939A ZA945939B ZA 945939 B ZA945939 B ZA 945939B ZA 945939 A ZA945939 A ZA 945939A ZA 945939 A ZA945939 A ZA 945939A ZA 945939 B ZA945939 B ZA 945939B
- Authority
- ZA
- South Africa
- Prior art keywords
- insulin
- formulation
- zinc
- total
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/106,106 US5534488A (en) | 1993-08-13 | 1993-08-13 | Insulin formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA945939B true ZA945939B (en) | 1996-02-08 |
Family
ID=22309529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA945939A ZA945939B (en) | 1993-08-13 | 1994-08-08 | Insulin formulation |
Country Status (27)
Country | Link |
---|---|
US (1) | US5534488A (hu) |
EP (1) | EP0646379B1 (hu) |
JP (1) | JPH07149660A (hu) |
KR (1) | KR950005324A (hu) |
CN (1) | CN1109364A (hu) |
AT (1) | ATE207761T1 (hu) |
AU (1) | AU674975B2 (hu) |
BR (1) | BR9403204A (hu) |
CA (1) | CA2129763A1 (hu) |
CO (1) | CO4230235A1 (hu) |
CZ (1) | CZ193794A3 (hu) |
DE (1) | DE69428860T2 (hu) |
DK (1) | DK0646379T3 (hu) |
ES (1) | ES2164691T3 (hu) |
HU (1) | HUT67853A (hu) |
IL (1) | IL110581A0 (hu) |
NO (1) | NO942959L (hu) |
NZ (1) | NZ264197A (hu) |
PE (1) | PE14495A1 (hu) |
PH (1) | PH30757A (hu) |
PL (1) | PL177002B1 (hu) |
PT (1) | PT646379E (hu) |
RU (1) | RU2135205C1 (hu) |
TW (1) | TW326394B (hu) |
UA (1) | UA27874C2 (hu) |
YU (1) | YU50494A (hu) |
ZA (1) | ZA945939B (hu) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578238A (en) * | 1992-10-30 | 1996-11-26 | Lord Corporation | Magnetorheological materials utilizing surface-modified particles |
AR002976A1 (es) * | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
EP1396272A1 (en) * | 1997-12-23 | 2004-03-10 | Eli Lilly & Company | Insoluble Insulin Compositions for Controlling Blood Glucose |
CO4970787A1 (es) * | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
EP1196446A1 (en) * | 1999-06-29 | 2002-04-17 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
JP2003528149A (ja) * | 2000-03-24 | 2003-09-24 | ジェネンテック・インコーポレーテッド | 軟骨性疾患の治療のためのインスリンの使用 |
JP4303959B2 (ja) * | 2000-10-06 | 2009-07-29 | ジ アドバイザー − ディフェンス リサーチ アンド ディベラップメント オーガナイゼイション | 磁気感受性流体組成物およびその調製方法 |
EP1344229B1 (en) * | 2000-11-29 | 2008-03-05 | The Adviser Defence Research & Development Organisation, Ministry of Defence, Government of India | A magnetorheological fluid composition and a process for preparation thereof |
CA2431033A1 (en) * | 2001-02-09 | 2002-08-22 | Genentech, Inc. | Crystallization of igf-1 |
DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
ES2664189T3 (es) | 2002-01-09 | 2018-04-18 | Emisphere Technologies, Inc. | Polimorfos de 4-(4-cloro-2-hidroxibenzoil)aminobutanoato de sodio |
DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
EP1711220A1 (en) * | 2004-01-16 | 2006-10-18 | Biodel, Inc. | Sublingual drug delivery device |
US20080085298A1 (en) * | 2004-03-12 | 2008-04-10 | Biodel, Inc. | Rapid Mucosal Gel or Film Insulin Compositions |
PT1740154E (pt) * | 2004-03-12 | 2009-09-11 | Biodel Inc | Composições de insulina com absorção melhorada |
US20080090753A1 (en) * | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
AU2005240213B8 (en) | 2004-05-06 | 2011-10-20 | Emisphere Technologies, Inc. | Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate |
MXPA06013251A (es) * | 2004-05-14 | 2007-02-28 | Emisphere Tech Inc | Compuestos y composiciones de aril-cetona para suministrar agentes activos. |
UA91512C2 (ru) | 2004-07-19 | 2010-08-10 | Биокон Лимитед | Коньюгати олигомеров инсулина, их композиция (варианты) и применение |
CN101014360A (zh) * | 2004-08-03 | 2007-08-08 | 埃米斯菲尔技术公司 | 抗糖尿病口服胰岛素-双胍组合物 |
US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
MX2008013165A (es) * | 2006-04-12 | 2009-01-29 | Biodel Inc | Formulaciones de combinacion de insulina de accion rapida y accion larga. |
PL2134351T3 (pl) | 2007-03-13 | 2017-10-31 | Jds Therapeutics Llc | Sposoby i kompozycje do przedłużonego uwalniania chromu |
WO2008124522A2 (en) * | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
CA2711561A1 (en) * | 2008-01-04 | 2009-07-16 | Biodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 glp-1 효능제의 병용물 |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
EP3345593B1 (de) | 2009-11-13 | 2023-09-06 | Sanofi-Aventis Deutschland GmbH | Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin |
TR201809460T4 (tr) | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
WO2011103575A1 (en) * | 2010-02-22 | 2011-08-25 | Case Western Reserve University | Long-acting insulin analogue preparations in soluble and crystalline forms |
ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
CN105749253A (zh) | 2011-03-01 | 2016-07-13 | Jds治疗有限公司 | 用于预防和治疗糖尿病、低血糖症及相关病症的胰岛素和铬组合物 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US11865121B2 (en) | 2016-02-11 | 2024-01-09 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2626228A (en) * | 1945-05-17 | 1953-01-20 | Novo Terapeutisk Labor As | Method of producing crystalline insulin |
US2882202A (en) * | 1950-04-05 | 1959-04-14 | Novo Terapeutisk Labor As | Insulin crystal preparations and methods of producing them |
US2882203A (en) * | 1951-06-26 | 1959-04-14 | Novo Terapeutisk Labor As | Injectable insulin preparation with protracted effect |
US2849370A (en) * | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
US2819999A (en) * | 1953-11-13 | 1958-01-14 | Novo Terapeutisk Labor As | Process for crystallization of insulin using freeze dried insulin as seeding material |
US2799622A (en) * | 1953-11-14 | 1957-07-16 | Novo Terapeutisk Labor As | Process of producing insulin crystals of substantially uniform size and compositions thereof |
US3060093A (en) * | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
DE2933946A1 (de) * | 1979-08-22 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Insulinkristallsuspension und verfahren zu ihrer herstellung. |
FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
-
1993
- 1993-08-13 US US08/106,106 patent/US5534488A/en not_active Expired - Fee Related
-
1994
- 1994-08-04 HU HU9402287A patent/HUT67853A/hu unknown
- 1994-08-08 PE PE1994248043A patent/PE14495A1/es not_active Application Discontinuation
- 1994-08-08 ZA ZA945939A patent/ZA945939B/xx unknown
- 1994-08-08 NZ NZ264197A patent/NZ264197A/en unknown
- 1994-08-08 BR BR9403204A patent/BR9403204A/pt not_active Application Discontinuation
- 1994-08-08 IL IL11058194A patent/IL110581A0/xx not_active IP Right Cessation
- 1994-08-09 UA UA94085696A patent/UA27874C2/uk unknown
- 1994-08-09 NO NO942959A patent/NO942959L/no not_active Application Discontinuation
- 1994-08-09 RU RU94028671A patent/RU2135205C1/ru active
- 1994-08-09 CO CO94035010A patent/CO4230235A1/es unknown
- 1994-08-09 PT PT94305883T patent/PT646379E/pt unknown
- 1994-08-09 KR KR1019940019550A patent/KR950005324A/ko active IP Right Grant
- 1994-08-09 DE DE69428860T patent/DE69428860T2/de not_active Expired - Fee Related
- 1994-08-09 PL PL94304600A patent/PL177002B1/pl unknown
- 1994-08-09 PH PH48764A patent/PH30757A/en unknown
- 1994-08-09 DK DK94305883T patent/DK0646379T3/da active
- 1994-08-09 CA CA002129763A patent/CA2129763A1/en not_active Abandoned
- 1994-08-09 ES ES94305883T patent/ES2164691T3/es not_active Expired - Lifetime
- 1994-08-09 AT AT94305883T patent/ATE207761T1/de not_active IP Right Cessation
- 1994-08-09 EP EP94305883A patent/EP0646379B1/en not_active Expired - Lifetime
- 1994-08-09 TW TW083107259A patent/TW326394B/zh active
- 1994-08-10 JP JP6188204A patent/JPH07149660A/ja not_active Withdrawn
- 1994-08-10 CZ CZ941937A patent/CZ193794A3/cs unknown
- 1994-08-10 YU YU50494A patent/YU50494A/sh unknown
- 1994-08-10 CN CN94109082A patent/CN1109364A/zh active Pending
- 1994-08-12 AU AU70247/94A patent/AU674975B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
DK0646379T3 (da) | 2001-12-03 |
PL304600A1 (en) | 1995-02-20 |
KR950005324A (ko) | 1995-03-20 |
PL177002B1 (pl) | 1999-09-30 |
RU2135205C1 (ru) | 1999-08-27 |
ES2164691T3 (es) | 2002-03-01 |
CN1109364A (zh) | 1995-10-04 |
NZ264197A (en) | 1997-01-29 |
BR9403204A (pt) | 1995-04-18 |
CZ193794A3 (en) | 1995-03-15 |
YU50494A (sh) | 1997-01-08 |
DE69428860T2 (de) | 2002-05-02 |
UA27874C2 (uk) | 2000-10-16 |
IL110581A0 (en) | 1994-11-11 |
AU7024794A (en) | 1995-02-23 |
PH30757A (en) | 1997-10-17 |
JPH07149660A (ja) | 1995-06-13 |
AU674975B2 (en) | 1997-01-16 |
EP0646379A1 (en) | 1995-04-05 |
DE69428860D1 (de) | 2001-12-06 |
NO942959L (no) | 1995-02-14 |
NO942959D0 (no) | 1994-08-09 |
HU9402287D0 (en) | 1994-09-28 |
PT646379E (pt) | 2002-03-28 |
PE14495A1 (es) | 1995-06-02 |
EP0646379B1 (en) | 2001-10-31 |
HUT67853A (en) | 1995-05-29 |
TW326394B (en) | 1998-02-11 |
ATE207761T1 (de) | 2001-11-15 |
CA2129763A1 (en) | 1995-02-14 |
CO4230235A1 (es) | 1995-10-19 |
US5534488A (en) | 1996-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH30757A (en) | Insulin formulation. | |
AU610636B2 (en) | Stabilised human protein preparations | |
IL72494A0 (en) | Homologues of aprotinin with other aminoacids in position 15,instead of lysine,their preparation and pharmaceutical compositions containing them | |
WO1995013297A3 (en) | Improved immunogenic compositions against human gastrin 17 | |
DK168790D0 (hu) | ||
CA2015186A1 (en) | Nutrient composition | |
NZ228710A (en) | Modified "echistatin" and anti-clotting pharmaceutical composition | |
AU2670495A (en) | Ifn-beta liquid formulations | |
AU8188087A (en) | Variants of hirudin, their use and their preparation | |
EP0265214A3 (en) | Polypeptide preparation | |
AU6406590A (en) | Porcine lactoferrin amino acid and cdna sequence | |
AU4225385A (en) | After-treating nylon or natural polyamides | |
HU9402648D0 (en) | 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens | |
MD1714G2 (ro) | Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină | |
CA2168570A1 (en) | Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid | |
AU2557288A (en) | Synergistic antifungal protein and compositions containing same | |
CA2153071A1 (en) | Derivatized calcitonins | |
EP0292302A3 (en) | Human splenin | |
HU201445B (en) | Herbicide composition containing sulfonyl-urea derivative as active component and glycinamide derivative as antidotum | |
GB8902372D0 (en) | Production of compositions containing the thyrotropin-releasing hormone(trh)or homologues thereof for uses in the regulation of the immune and related systems | |
TH17521A (th) | สูตรผสมอินซูลิน | |
AU6985287A (en) | 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3- {(substituted amino)carbonyl}-2-thioxo(or oxo)-5-pyrimidine -carboxylic acids and esters | |
TH17521EX (th) | สูตรผสมอินซูลิน |